Travere Therapeutics Inc (NASDAQ: TVTX) is 19.46% higher on its value in year-to-date trading and has touched a low of $5.30 and a high of $25.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TVTX stock was last observed hovering at around $20.08 in the last trading session, with the day’s gains setting it 0.73%.
Currently trading at $20.81, the stock is 28.35% and 11.95% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.51 million and changing 3.64% at the moment leaves the stock 26.94% off its SMA200. TVTX registered 295.63% gain for a year compared to 6-month gain of 18.71%. The firm has a 50-day simple moving average (SMA 50) of $18.5891 and a 200-day simple moving average (SMA200) of $16.39345.
The stock witnessed a 16.13% loss in the last 1 month and extending the period to 3 months gives it a 1.76%, and is 24.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.19% over the week and 7.99% over the month.
Travere Therapeutics Inc (TVTX) has around 385 employees, a market worth around $1.85B and $233.18M in sales. Fwd P/E is 17.80. Profit margin for the company is -137.90%. Distance from 52-week low is 292.64% and -17.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-83.18%).
with sales reaching $76.86M over the same period.The EPS is expected to grow by 67.89% this year, but quarterly earnings will post 65.37% year-over-year. Quarterly sales are estimated to grow 85.76% in year-over-year returns.
281.0 institutions hold shares in Travere Therapeutics Inc (TVTX), with institutional investors hold 110.09% of the company’s shares. The shares outstanding are 87.45M, and float is at 87.44M with Short Float at 12.63%. Institutions hold 109.32% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.64 million shares valued at $62.84 million. The investor’s holdings represent 9.8642 of the TVTX Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 7.5 million shares valued at $61.65 million to account for 9.6774 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 7.37 million shares representing 9.5096 and valued at over $60.58 million, while VANGUARD GROUP INC holds 8.5416 of the shares totaling 6.62 million with a market value of $54.41 million.
Travere Therapeutics Inc (TVTX) Insider Activity
The most recent transaction is an insider sale by Cline Christopher R., the company’s CHIEF FINANCIAL OFFICER. SEC filings show that Cline Christopher R. sold 48 shares of the company’s common stock on Apr 11 ’25 at a price of $13.14 per share for a total of $631.0. Following the sale, the insider now owns 89990.0 shares.
Still, SEC filings show that on Feb 12 ’25, ROTE WILLIAM E. (SENIOR VICE PRESIDENT, R&D) disposed off 5,200 shares at an average price of $23.53 for $0.12 million. The insider now directly holds 98,519 shares of Travere Therapeutics Inc (TVTX).
